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Background. The liability-threshold model of psychosis risk predicts stronger phenotypic manifestation of the polygenic
risk score (PRS) in the healthy relatives of patients, as compared with healthy comparison subjects.
Methods. First-degree relatives of patients with psychotic disorder (871 siblings and 812 parents) and healthy compari-
son subjects (n = 523) were interviewed three times in 6 years. Repeated measures of two psychosis phenotypes, the
Community Assessment of Psychic Experiences (CAPE; self-report – subscales of positive, negative and depressive
symptoms) and the Structured Interview for Schizotypy – Revised (SIS-R; clinical interview – subscales of positive and
negative schizotypy), were examined for association with PRS. Interview-based lifetime rate of depressive and manic
episodes were also examined, as was association with repeated measures of intelligence quotient (IQ).
Results. In the relatives, PRS was associated with CAPE/SIS-R total score (respectively, B = 0.12, 95% CI 0.02–0.22
and B = 0.11, 95% CI 0.02–0.20), the SIS-R positive subscale (B = 0.16, 95% CI 0.04–0.28), the CAPE depression subscale
(B = 0.21, 95% CI 0.07–0.34), any lifetime affective episode (OR 3.1, 95% CI 1.04–9.3), but not with IQ (B =−1.8, 95%
CI −8.0 to 4.4). In the controls, similar associations were apparent between PRS on the one hand and SIS-R total
score, SIS-R positive, SIS-R negative, any lifetime affective episode and, in contrast, lower IQ (B =−8.5, 95% CI −15.5
to −1.6).
Conclusions. In non-ill people, polygenic risk for psychotic disorder is expressed pleiotropically in the domain of neu-
rodevelopment, emotion regulation and attribution of salience. In subjects at elevated genetic risk, emerging expression
of neurodevelopmental alterations may create ﬂoor effects, obscuring genetic associations.
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Introduction
There is strong evidence that measures of psychosis
proneness in non-clinical populations are associated
with a family history of psychotic disorder (Linscott
& van Os, 2013; Jeppesen et al. 2015). However, early
reports on associations between measures of psychosis
proneness in the general population and genome-wide
association study (GWAS)-based polygenic risk scores
(PRS) for schizophrenia (International Schizophrenia
et al. 2009; Iyegbe et al. 2014) are inconclusive (Sieradzka
et al. 2014; Zammit et al. 2014; Jones et al. 2016; van
Os, 2016). Any association between psychosis prone-
ness and PRS may be stronger in relatives of patients,
compared with the general population, given that
expression of psychosis-related phenotypes likely is
attributable to genes shared with the patient relative
(Kendler et al. 1993; Cardno et al. 1999), whereas
expression of psychosis-related phenotypes in general
population samples may be associated more with
environmental effects (Van Os et al. 2010; Linscott &
van Os, 2013; Svrakic et al. 2013). We therefore
hypothesized that the link between PRS and expres-
sion of psychosis phenotypes would be stronger in
relatives of patients, who share liability genes with
their ill relative, as compared with the general popula-
tion, whose level of genetic liability is much lower.
Data pertained to patients with psychotic disorder
(n = 1119), their parents (n = 920) and siblings (n =
1059) and healthy comparison subjects (n = 586)
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participating in the baseline, 3-year and 6-year
follow-up assessments of the Genetic Risk and
Outcome of Psychosis (GROUP) study. Repeated mea-
sures of two psychosis phenotypes, indexed with the
Community Assessment of Psychic Experiences
(CAPE; self-report) and the Structured Interview for
Schizotypy – Revised (SIS-R; clinical interview), were
examined for association with PRS. Given strong
associations between psychosis phenotypes and mea-
sures of affective dysregulation (Verdoux et al. 1999;
Hanssen et al. 2003; Van Rossum et al. 2011; Varghese
et al. 2011; Wigman et al. 2012; Stochl et al. 2015), affect-
ive outcomes were also included in the analyses. Given
the commonly hypothesized notion that genetic effects
in schizophrenia are mediated through altered neuro-
development (Hubbard et al. 2016), neurocognition
was also examined in relation to PRS.
Methods
GROUP study
Full details of the GROUP study have been presented
elsewhere (Steinberg et al. 2011; Korver et al. 2012). In
representative geographical areas in the Netherlands
and Belgium, patients were identiﬁed through clini-
cians working in regional psychotic disorder services,
whose caseload was screened for inclusion criteria.
Subsequently, a group of patients presenting at these
services either as out-patients or in-patients were
recruited for the study. Healthy comparison subjects
were selected through random mailings to addresses
in the catchment areas of the cases. The GROUP study
was not conducted in a geographically well-deﬁned
small area, as it in fact included the majority of mental
health services in the Netherlands, and a substantial
part of mental health services in Dutch-speaking
Belgium. Healthy comparison subjects could not be rep-
resentative in all aspects, as an exclusion criterion was
absence of a family history of psychotic disorder. The
goal was to collect a group of healthy comparison sub-
jects that (i) was collected from the same geographical
area as the case in the relevant mental health service,
(ii) was sufﬁciently large to allow for chance variation
and (iii) was frequency-matched in age- and sex distri-
bution to the siblings and (iv) had absence of family his-
tory of psychotic disorder. Table 1 shows that healthy
comparison subjects, siblings and parents had similar
sex distributions whilst healthy comparison subjects
and siblings did not have large differences in age.
Sample
The full GROUP sample at baseline consisted of 1119
patients with non-affective psychotic disorder, 1059
siblings of these patients, 920 parents of the patients
and 586 unrelated healthy comparison subjects.
Inclusion criteria were: (i) age range 16–50 years and
(ii) good command of Dutch language. For patients,
an additional inclusion criterion was the presence of
a clinical diagnosis of non-affective psychotic disorder.
Healthy comparison subjects status was conﬁrmed
by using the Family Interview for Genetic studies
(NIMH.Genetics.Initiative, 1992) with the healthy com-
parison subject as informant, to establish absence of
ﬁrst degree relatives with a psychotic disorder.
Diagnosis was based on the Diagnostic and Statistical
Manual of Mental Disorder-IV (DSM-IV) criteria
(American Psychiatric Association, 2000), assessed with
the Comprehensive Assessment of Symptoms and
History (CASH) interview (Andreasen et al. 1992) or
Schedules for Clinical Assessment for Neuropsychiatry
(SCAN 2.1) (Wing et al. 1990). The majority of patients
had a DSM-IV diagnosis of schizophrenia (DSM-IV 295.
x; n = 940, 84%). In the sibling and healthy comparison
subject groups, there were respectively, 154 (14%) and
59 participants (10%) with a history of a commonmental
disorder at baseline, the majority of whom had a mood
disorder (DSM-IV 296.x).
The study was approved by the standing ethics com-
mittee, and all the subjects gave written informed con-
sent in accordance with the committee’s guidelines.
Sample for analysis
For the purpose of the current analyses, siblings, par-
ents and healthy comparison subjects groups were
included. Analyses were restricted to the European
white ethnic group (n = 2218, or 87% out of a total of
2565 siblings, parents and healthy comparison subjects
groups at baseline) given the fact that prevalence of
risk alleles varies widely across ethnic groups, as
may the risk associated with individual alleles, and evi-
dence exists of differential effects of PRS across ethnic
groups (Marden et al. 2014). Observations of siblings
and healthy comparison subjects who made a possible
(n = 2, of whom 1 of European white ethnic group) or
deﬁnite (n = 16, of whom 11 of European white ethnic
group) transition to a psychotic disorder over the
follow-up period, and thus were re-classiﬁed as
patients, were excluded from analysis. Applying ethni-
city and transition criteria thus resulted in a baseline
sample of 523 healthy comparison subjects, 871 siblings
and 812 parents of siblings (total sample: n = 2206). Of
the 2206, the number of individuals with data permit-
ting calculation of the PRS was 1578 (72%) with approxi-
mately equal proportions across healthy comparison
subjects (73%), siblings (67%) and parents (75%).
SIS-R
The SIS-R was administered to healthy comparison
subjects, parents and siblings. The SIS-R is a semi-
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structured interview containing 20 schizotypal symp-
toms and 11 schizotypal signs rated on a 4-point
scale (Kendler et al. 1989; Vollema & Ormel, 2000).
Symptoms are deﬁned as verbal responses to standar-
dized questions concerning, for example, magical idea-
tion, illusions and referential thinking. Signs refer to
behaviours that are rated by the interviewer such as
goal directedness of thinking and ﬂatness of affect.
Questions and rating procedures are standardized.
Guided by previous research, 33 item scores were
reduced a priori to two-dimensional scores, represent-
ing the means of seven positive schizotypy items
(covering the areas of referential thinking, psychotic
phenomena, derealisation, magical ideation, illusions
and suspiciousness) and eight negative-disorganized
schizotypy items (covering the areas of social isolation,
sensitivity, introversion, restricted affect, disturbances
in associative and goal-directed thinking, poverty of
speech and eccentric behaviour).
CAPE
The CAPE (www.cape42.homestead.com) was devel-
oped in order to rate self-reports of lifetime psychotic
experiences (Konings et al. 2006). Items are modelled
on patient experiences as contained in the Present
State Examination, 9th version (Wing et al. 1974), sche-
dules assessing negative symptoms such as the Scale
for the Assessment of Negative Symptoms (SANS)
(Andreasen, 1982) and the Subjective Experience of
Negative Symptoms (SENS) (Selten et al. 1993) and
scales assessing depressive symptoms such as the
Calgary Depression Scale (Addington et al. 1993).
Items are scored on a 4-point scale. In the current
analyses, CAPE dimensions of frequency of positive
experiences (20 items), negative experiences (14
items) and depressive experiences (eight items) were
included (measured at baseline and 3- and 6-year
follow-up), representing the person’s perceived psych-
osis load over the lifetime (at baseline) or in the past 3
years (follow-up). A total score representing the mean
of all items was calculated for each dimension.
Manic and depressive episodes
Lifetime rate of depressive and manic episodes were
derived from the CASH interview (data available for
3 of the 4 centres).
Intelligence quotient (IQ)
At baseline and 3-year follow- = up, IQ was estimated
based on the four-subtest version (Information, Block
Design, Digit Symbol Coding and Arithmetic) (Blyler
et al. 2000) of the Wechsler Adult Intelligence Scale
(WAIS-III) (Wechsler, 1997). At 6-year follow-up, IQ
was estimated based on a short version of the
WAIS-III short form: the Digit Symbol Coding subtest,
uneven items of the Arithmetic subtest, uneven items
of the Block Design subtest, every third item of the
Information subtest (Velthorst et al. 2013).
Follow-up
Healthy comparison subjects and siblings were eligible
for follow-up; parents were only assessed at baseline.
Of the 523 healthy comparison subjects and 871 siblings
at baseline, 80% (n = 1115) were assessed at 3-year
follow-up (healthy comparison subjects: 79%, n = 415;
siblings: 80%, n = 700) and 69% (n = 973) at 6-year
follow-up (healthy comparison subjects: 68%, n = 357;
siblings: 71%, n = 616). Ratings of CASH, SCAN, SIS-R
and CAPE at follow-up reﬂected the period between
baseline and ﬁrst follow-up, and between ﬁrst and
second follow-up, respectively. Mean time to ﬁrst
follow-up was 3.3 years (S.D. = 0.5) and mean between
ﬁrst and second follow-up was 3.1 years (S.D. = 0.4).
Genotyping, imputation and PRS
Genotyping was performed using two platforms. A
total of 1434 participants (758 patients, 676 healthy
Table 1. Baseline demographics of GROUP participants in current analysis
Age
% Female
Educationa IQ
Urbanicity at
birthb
NMean S.D. Mean S.D. Mean S.D. Mean S.D.
Healthy comparison subjects 31.10 10.70 0.55 2.95 1.27 110.16 14.79 2.57 1.68 523
Sibs 27.85 8.32 0.53 2.63 1.48 104.00 15.22 2.52 1.63 871
Parents 54.83 6.83 0.57 2.53 1.57 103.54 16.68 2.26 1.58 812
Total 38.55 15.08 0.55 2.69 1.46 105.31 15.90 2.51 1.64 2206
a Education (Verhage): range 0 (no education), 3–5 (school diploma) to 8 (university degree).
b Urbanicity: 1 = <500/km2; 2 = 500–1000/km2; 3 = 1000–1500/km2; 4 = 1500–2500/km2; 5 = 2500+/km2.
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comparison subjects) were genotyped on the Illumina
platform for 547 383 SNPs on the Illumina
HumanHap 550k v3.0 beadchip. A second group of
1968 participants (393 patients, 154 controls and 1421
healthy relatives) were genotyped for 929 556 SNPs
using the Affymetrix genome-wide Human SNP
Array version 6.0.
A binary data set of the Illumina platform was gen-
erated including 547 383 genotyped variants in 1434
subjects. We excluded 36 samples showing a sex mis-
match between recorded and the genetically deter-
mined gender type, leaving 1,398 people for further
analysis. We excluded SNPs that were haploid or had
missing rates per SNP of >0.10, or a MAF of <0.01 or
a HWE p value<0. 00001 (in healthy comparison sub-
jects) and excluded individuals, with a missing rate
>10%, altogether yielding 515 286 variants and 1393
individuals (737 patients and 656 healthy comparison
subjects) for further analysis. Next, a binary data set
of Affymetrix platform was generated including 929
556 SNPs genotyped in 1968 subjects (393 patients
and 1575 relatives), of which 729 597 SNPs and 1968
individuals passed the standard quality processing
checks. We successfully converted genetic coordination
of all variants (except for 57 from Illumina and 86 from
Affymetrix) from Human NCBI36/hg18 to GRCh37/
hg19 using Liftover (online tools) for all samples.
Next, we imputed both platform samples on the back-
bone of 1000 G Phase-3 reference haploblocks, as
implemented in the Haplotype Reference Consortium
(HRC) (McCarthy et al. 2016), using the Michigan
Imputation Server and the SHAPEIT option for phas-
ing. This yielded 46 178 415 imputed variants, which
was reduced to 16 353 433 SNPs after selecting SNPs
with a quality score (info score) threshold of >0.30, of
which 9 067 392 variants and 1393 subjects passed the
post-imputation QC. As for Affymetrix genotypes,
1kG-based imputation yielded 46 178 419 imputed
SNPs, which were reduced to 9 122 501 SNPs after
implementing post-imputation quality controls in
1968 subjects. These were included in the next step.
In order to calculate PRS, we obtained summary
statistics of the genome-wide association study from
the Psychiatric Genomic Consortium-2 (PGC2)
(Schizophrenia Working Group of the Psychiatric
Genomics, 2014), which included the GROUP subjects.
We performed meta-analysis again while excluding
GROUP samples as well as other Dutch samples,
including a total of 17 104 566 SNPs, of which 8 242
976 SNPs were common with imputed GROUP
genotypes from Illumina-based variants and 8 290 712
variant from Affymetrix-based variants. Following
the approach taken by the international psychiatric
GWAS consortium, we calculated a PRS at the metag-
was p-threshold of <0.1 for association with
Schizophrenia by PGC2. This included 2 302 038
SNPs of which 1 481 064 SNPs were common with
the Illumina genotype dataset, and 1 483 770 SNPs
were common with the Affymetrix genotype data set
(1 455 047 SNPs are common across both platforms).
Furthermore, we repeated our association analysis at
p-threshold of <0.01, which constituted 449 794 SNPs
(364 121common with the Illumina platform, 363
305common with the Affymetrix platform and 360
150 SNPs common across both platforms). We used
PRSice (Euesden et al. 2015) software to calculate
PRS; by LD clumping of r2 value < 0.2, at distance
threshold of 250 kb, while adjusting for 10 eigenvectors
calculated by Eigenstrat (Price et al. 2006). This led to
inclusion of 119 653 SNPs from the Illumina platform
and 119 271 SNPs from Affymetrix for estimating
PRS at p-metagwas<0.1; and 25 250 SNPs from the
Illumina and 25 152 SNPs from the Affymetrix plat-
form to estimate PRS at p-metagwas<0.01. We calcu-
lated different PRS using different p value thresholds,
from 0 to 0.50, and checked the explained variances
at the different threshold of PRS on schizophrenia
using Nagelkerke’s R-square. The analyses are based
on the p-threshold of 0.01 with sensitivity analyses
for the p-threshold of 0.1. For ease of interpretation, a
constant was added to the two PRS scores, so that
the minimum value was 0.
Analyses
GROUP database version 5.0 was used for all analyses.
Random intercept multilevel regression models (given
clustering of individuals within families as well as
clustering of repeated measures within subjects) with
SIS-R and CAPE measures as dependent variables
were ﬁtted using the MIXED routine in the Stata pro-
gram, version 14 (StataCorp, 2015). Independent vari-
ables were PRS, a priori corrected for age and sex. In
addition, binary outcomes of CASH lifetime depressive
and manic episode were modelled using the Stata
MEQRLOGIT multilevel random intercept logistic
regression routine, similarly adjusted for age and sex.
In order to examine robustness of ﬁndings with
regard to assumptions of normality, log-transformed
outcomes were additionally examined, using the
Stata LNSKEW0 routine. LNSKEW0 creates newvar =
ln(+/−exp− k), choosing k and the sign of exp so that
the skewness of newvar is zero.
In order to assess to what degree associations
between PRS and measures of psychosis proneness
were independent, regression analyses were conducted
for one measure of psychosis proneness, corrected for
all the others. In order to examine to what degree
any association between PRS and measures of psych-
osis proneness were mediated by IQ, IQ was added
to the analyses as a covariate.
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Results
Descriptive results and interaction by group
Sample characteristics are displayed in Table 1. Values
of the CAPE and SIS-R total score, lifetime depressive
and manic episodes and PRS are shown in Table 2,
by group and sex. CAPE and SIS-R subscale scores,
by group and sex, are shown in Table 3.
The PRS of the healthy comparison subjects (0.60,
S.D. = 0.21) was signiﬁcantly lower than the PRS in the
combined group of parents and siblings (0.83, S.D. =
0.15; p < 0.001). The PRS in the group of parents and
siblings was signiﬁcantly correlated with the PRS in
the patient group (r = 0.30, p < 0.0001).
Graphical examination of the scatterplots of PRS on
the one hand and CAPE / SIS-R total scores (Fig. 1a–d),
CAPE subscale scores (Fig. 2a–f), SIS-R subscales scores
(Fig. 3a–d) and IQ (Fig. 4a, b) on the other suggests
association between PRS and various aspects of psy-
chopathology and cognition in both groups.
Associations in relatives and healthy comparison
subjects
Given the graphical suggestion of differences in the pat-
tern of associations, analyses were conducted separately
for relatives and the healthy comparison group. The
pattern of correlation between the CAPE and SIS-R
total and subscale scores were similar for relative and
healthy comparison subjects, in that within-instrument
scale correlations were high, whereas between-scale
correlations were only moderate (Table 4).
Results of the multilevel random regression analyses
are shown in Tables 5–7. In the relatives (Table 6), PRS
was associated with CAPE total score (B = 0.12, 95% CI
0.02–0.22, p = 0.015), SIS-R total score (B = 0.11, 95% CI
0.02–0.20, p = 0.013) as well as with CAPE depression
(B = 0.21, 95% CI 0.07–0.34, p = 0.004) and the SIS-R
positive subscale (B = 0.16, 95% CI 0.04–0.28, p =
0.008). Analyses with log-transformed scales showed
similar results (Table 5). Analyses of the CAPE the
SIS-R subscales, in which subscales were controlled
for each other, showed that associations were reducible
to the association with CAPE depression, which con-
tinued to be associated with PRS (B = 0.10, 95% CI
0.02–0.19, p = 0.021) whereas the association with the
SIS-R positive subscale was rendered non-signiﬁcant
(Table 5).
The association between CAPE depression and PRS
was not affected by IQ, as the association with CAPE
depression remained similar when IQ was added in
addition to age and sex (B = 0.20, 95% CI 0.06–0.34, p
= 0.005).
In the healthy comparison subjects (Table 6), PRS
was associated with the SIS-R total score (B = 0.16,
95% CI 0.07–0.25, p = 0.000) and both the SIS-R positive
subscale (B = 0.22, 95% CI 0.10–0.35, p = 0.000) and the
SIS-R negative subscale (B = 0.11, 95% CI 0.03–0.19,
p = 0.10) (Table 6). Analyses with log-transformed
scales were similar (Table 6). In the analysis in which
all subscales were controlled for each other, only the
association with the SIS-R positive subscale remained
signiﬁcant (B = 0.14, 95% CI 0.05–0.24, p = 0.004;
Table 6).
Analyses of association between PRS and CASH-
based lifetime depressive and manic episodes revealed
evidence for association in both the relatives (OR any
affective episode = 5.2, 95% CI 1.6–16.7, p = 0.006) and
the healthy comparison subjects (OR any affective
episode = 4.0, 95% CI 1.2–13.1, p = 0.021) (Table 7).
In the relatives, no large or signiﬁcant association
was apparent between PRS and IQ in a separate
model of IQ, corrected for age and sex (B =−1.8, 95%
CI −8.0 to 4.4; p = 0.566). In the healthy comparison
subjects, there was evidence for an association between
IQ and PRS, adjusted for age and sex (B =−8.5, 95% CI
−15.5 to −1.6; p = 0.017). The association between PRS
and IQ in the healthy comparison subjects remained
after controlling for SIS-R total score (B =−7.5, 95%
CI −14.5 to −0.4; p = 0.038). Similarly, the association
between PRS and SIS-R total score in the healthy com-
parison subjects remained after controlling for IQ (B =
0.16, 95% CI 0.07–0.25; p = 0.001).
Sensitivity analyses at PRS p-threshold of 0.1
Results for the sensitivity analyses were at the PRS
p-threshold of 0.1 were very similar to the analyses at
the P-threshold of 0.01. The association between PRS
and IQ was slightly weaker in the healthy comparison
group (B =−7.1, 95% CI −15.1 to 0.9, p = 0.081). In the
relatives group, associations between PRS and the
CAPE positive and negative subscale were also signiﬁ-
cant and associations were not reducible to CAPE
depression but to the SIS-R positive subscale.
Discussion
The main ﬁndings were that (i) PRS was pleiotropically
associated with measures of affective dysregulation,
aberrant salience and neurocognition; (ii) The associ-
ation between neurocognition and PRS was present
in the healthy comparison subjects but not in the rela-
tives, and was independent of CAPE/SIS-R measures;
(iii) Interview-based SIS-R measures appeared to be
more sensitive than CAPE-based self-reports in detect-
ing genetic association in the healthy comparison
group.
According to the liability-threshold model, a person
with a number of risk variants lower than or equal to
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the critical threshold would not develop schizophrenia,
whereas a person with more risk variants would
(McGue et al. 1983). As individuals at higher than
average genetic risk, such as the ﬁrst-degree relatives
of patients, have higher levels of psychometric and
neurocognitive endophenotypes associated with
psychotic disorder (Kendler et al. 1993; Toulopoulou
et al. 2007), associations between PRS and such
Table 2. Depression and mania outcomes, and polygenic risk scores by group and by sex
% Depressive
episodea % Manic episodea PRS
Rate N Rate N Mean S.D. N
Group
Healthy comparison subjects 0.27 445 0.02 445 0.60 0.21 382
Sibs 0.33 656 0.04 656 0.83 0.15 586
Parents 0.30 583 0.02 583 0.83 0.15 610
Sex
Men 0.22 739 0.03 739 0.77 0.20 720
Women 0.37 945 0.03 945 0.77 0.19 858
Total 0.30 1684 0.03 1684 −0.28 0.55 1578
PRS, polygenic risk score.
a Lifetime rate, calculated with baseline sample as denominator and including episodes occurring over the 6-year post-
baseline follow-up period in the numerator.
Fig. 1. (a–d) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand, and, on the other,
Community Assessment of Psychic Experiences (CAPE) total score in healthy comparison subjects (Fig. 1a) Structured
Interview for Schizotypy – Revised (SIS-R) total score in healthy comparison subjects (Fig. 1b), CAPE total score in relatives
(Fig. 1c) and SIS-R total score in relatives (Fig. 1d).
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Table 3. Cape and SIS-R subscale scores by group and by sex
Time
CAPE total CAPE-POS CAPE-NEG CAPE-DEP SIS-R total
SIS-R
positive
SIS-R
negative
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. n Mean S.D.
Group
1 HCS 0.42 0.23 502 0.19 0.17 500 0.48 0.32 500 0.59 0.34 502 0.27 0.25 515 0.30 0.35 515 0.24 0.23 514
Siblings 0.45 0.27 767 0.19 0.18 765 0.54 0.38 765 0.61 0.38 767 0.31 0.28 858 0.36 0.41 858 0.26 0.24 858
Parentsa 0.41 0.23 692 0.13 0.13 692 0.50 0.33 692 0.60 0.35 692 0.29 0.24 806 0.25 0.30 806 0.32 0.28 806
2 HCS 0.30 0.23 401 0.08 0.12 401 0.39 0.31 400 0.43 0.35 401 0.26 0.20 402 0.27 0.29 402 0.24 0.21 400
Siblings 0.35 0.28 675 0.10 0.14 673 0.46 0.40 674 0.49 0.40 675 0.29 0.25 683 0.31 0.34 683 0.28 0.25 683
Parentsa – – – – – – – – – – – – – – – – – – – – –
3 HCS 0.32 0.26 343 0.08 0.15 343 0.41 0.34 343 0.48 0.41 343 0.27 0.21 336 0.28 0.29 336 0.25 0.22 336
Siblings 0.35 0.28 594 0.08 0.12 593 0.47 0.40 593 0.50 0.41 594 0.30 0.24 598 0.31 0.31 598 0.29 0.25 598
Parentsa – – – – – – – – – – – – – – – – – – – – –
Sex
1 Men 0.40 0.23 890 0.17 0.16 889 0.50 0.33 889 0.52 0.32 890 0.28 0.25 984 0.28 0.33 984 0.29 0.27 983
Women 0.45 0.26 1071 0.17 0.17 1068 0.52 0.35 1068 0.67 0.38 1071 0.30 0.27 1195 0.33 0.38 1195 0.27 0.25 1195
2 Men 0.30 0.24 478 0.10 0.13 478 0.42 0.35 478 0.40 0.34 478 0.27 0.23 486 0.26 0.30 486 0.27 0.25 485
Women 0.36 0.28 598 0.09 0.13 596 0.45 0.39 596 0.53 0.40 598 0.29 0.24 599 0.32 0.34 599 0.26 0.23 598
3 Men 0.31 0.25 419 0.09 0.13 418 0.43 0.36 418 0.42 0.36 419 0.29 0.24 420 0.28 0.30 420 0.29 0.27 420
Women 0.36 0.29 518 0.08 0.13 518 0.46 0.39 518 0.55 0.44 518 0.29 0.22 514 0.31 0.31 514 0.27 0.22 514
CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and depressive symptoms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of
positive and negative schizotypy).
a Parents baseline measures only.
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endophenotypes may be more apparent in this group.
However, in the current analysis, there was no evi-
dence that associations between PRS and measures of
psychopathology and cognition were stronger in the
relatives of patients as compared with a group of
healthy comparison subjects. Indeed, given stronger
evidence for association between PRS and cognition
in the healthy control group, the results suggest it
may be more, not less difﬁcult to demonstrate associa-
tions in the relatives.
A previous investigation in this sample, focussing on
the association between childhood trauma and IQ,
reported a similar ﬁnding in that the association
between IQ and childhood trauma was large in the
healthy comparison group, intermediate in the rela-
tives and not apparent in the patient group (Van Os
Fig. 2. (a–f) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand, and, on the other,
Community Assessment of Psychic Experiences (CAPE) positive score in healthy comparison subjects (Fig. 2a), CAPE
negative score in healthy comparison subjects (Fig. 2b), CAPE depression score in healthy comparison subjects (Fig. 2c), CAPE
positive score in relatives (Fig. 2d), CAPE negative score in relatives (Fig. 2e), CAPE depression score in relatives (Fig. 2f).
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et al. 2017). Thus, in subjects at higher than average
(environmental or genetic) risk, emerging expression
of phenotypic alterations may create ﬂoor effects,
obscuring associations. The results of this study
again suggest that particularly measures in the
neurodevelopmental domain may be sensitive to
such a ﬂoor effect, as associations between PRS and
subthreshold measures of psychopathology were
apparent in both the relative and the healthy compari-
son groups.
Fig. 3. (a–d) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand, and, on the other,
Structured Interview for Schizotypy – Revised (SIS-R) positive score in healthy comparison subjects (Fig. 3a), SIS-R negative
score in healthy comparison subjects (Fig. 3b), SIS-R positive score in relatives (Fig. 3c), SIS-R negative score in relatives
(Fig. 3d).
Fig. 4. (a, b) Scatterplots with linear regression line of polygenic risk score (PRS) on the one hand and, on the other,
intelligence quotient (IQ) score in the healthy comparison subjects (Fig. 4a) and IQ score in the relatives (Fig. 4b).
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Affective dysregulation, aberrant salience and genetic
liability to psychosis
There is a well-established link between affective
dysregulation and psychosis, both at the level of clin-
ical illness (Tsuang & Dempsey, 1979; McMillan et al.
2009), subthreshold psychotic experiences (Verdoux
et al. 1999; Hanssen et al. 2003; Van Rossum et al.
2011; Varghese et al. 2011; Wigman et al. 2012; Stochl
et al. 2015), so-called clinical high-risk states
(Fusar-Poli et al. 2014) and in the early prodromal
Table 4. Pattern of Pearson’s correlation coefﬁcients between psychopathology measures in relatives (top) and controls (bottom)
Relatives
SIS-R
total
CAPE
total
SIS-R
negative
CAPE
negative
SIS-R
positive
CAPE
positive
CAPE
depressive
SIS-R total 1
CAPE total 0.50 1
SIS-R negative 0.82 0.42 1
CAPE negative 0.45 0.92 0.43 1
SIS-R positive 0.88 0.42 0.44 0.35 1
CAPE positive 0.38 0.65 0.19 0.48 0.42 1
CAPE depressive 0.45 0.93 0.39 0.75 0.38 0.49 1
Healthy comparison subjects
SIS-R total 1
CAPE total 0.46 1
SIS-R negative 0.82 0.36 1
CAPE negative 0.40 0.90 0.36 1
SIS-R positive 0.89 0.42 0.46 0.33 1
CAPE positive 0.33 0.68 0.16 0.49 0.39 1
CAPE depressive 0.43 0.92 0.35 0.72 0.38 0.50 1
CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and depressive symptoms); SIS-R,
Structured Interview for Schizotypy – Revised (subscales of positive and negative schizotypy).
Table 5. Results of regression analyses in relatives of patients (B, regression coefﬁcient, 95% CI, 95% conﬁdence interval; p, p value;
n, number of observations)
Association of psychopathology
measure with PRS
Association of log-transformed
psychopathology measure with
PRS
Association of psychopathology
subscales with PRS, corrected for
the other subscales
B (95% CI) p n B (95% CI) p n B (95% CI) p n
Measure
CAPE total 0.12 (0.02–0.22) 0.015 1916 0.16 (0.01–0.31) 0.032 1916 NAa
CAPE positive 0.04 (−0.02 to 0.10) 0.150 1913 0.32 (−0.01 to 0.65) 0.059 1913 −0.01 (−0.05 to 0.04) 0.830 1884
CAPE negative 0.13 (−0.01 to 0.27) 0.075 1914 0.12 (−0.05 to 0.28) 0.170 1914 −0.04 (−0.13 to 0.05) 0.385 1884
CAPE depressive 0.21 (0.07–0.34) 0.004 1916 0.21 (0.07–0.36) 0.005 1916 0.10 (0.02–0.19) 0.021 1884
SIS-R total 0.11 (0.02–0.20) 0.013 2071 0.24 (0.04–0.43) 0.016 2071 NAa
SIS-R positive 0.16 (0.04–0.28) 0.008 2071 0.51 (0.19–0.83) 0.002 2071 0.08 (−0.02 to 0.18) 0.136 1884
SIS-R negative 0.08 (−0.02 to 0.17) 0.103 2071 0.14 (−0.06 to 0.33) 0.166 2071 0.02 (−0.06 to 0.10) 0.616 1884
a NA: analyses were conducted with the ﬁve subscales: CAPE positive, CAPE negative, CAPE depressive, SIS-R positive,
SIS-R negative.
PRS, polygenic risk score; CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and
depressive symptoms); SIS-R, Structured Interview for Schizotypy – Revised (subscales of positive and negative schizotypy).
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stages (Hafner et al. 1999). In addition, many studies
have suggested an important role of affective dysregu-
lation in the formation of psychotic symptoms
(Freeman & Garety, 1999; Garety et al. 2001; Freeman
& Garety, 2003; Myin-Germeys & van Os, 2007;
Fowler et al. 2012), and molecular genetic studies
suggest an overlap between schizophrenia and affect-
ive illness (Cross-Disorder Group of the Psychiatric
Genomics and Genetic Risk Outcome of Psychosis,
2013; Cross-Disorder Group of the Psychiatric
Genomics et al. 2013).
There is evidence that psychosis represents a sever-
ity dimension of an initial state of affective dysregula-
tion (Kelleher et al. 2012; Wigman et al. 2012) and that
clinical high risk samples with high risk of conversion
to psychotic disorder mainly consist of individuals
with affective dysregulation (Addington et al. 2007).
Therefore, early states of affective dysregulation may
give rise to more severe states in which psychotic
symptoms arise (Van Os & Reininghaus, 2016).
Additional exposure may be required for psychotic
symptom formation, research showing higher risks of
psychotic symptom formation with progressively
greater level of exposure to environmental risk factors
(Cougnard et al. 2007; Guloksuz et al. 2015; Van Nierop
et al. 2015).
The ﬁndings agree with the literature, suggesting
that the association between genetic risk and psychosis
proneness is not only mediated by psychoticism and
neurodevelopmental alterations, but also by measures
Table 6. Results of regression analyses in healthy comparison subjects (B, regression coefﬁcient, 95% CI, 95% conﬁdence interval; p, p value;
n, number of observations)
Association of psychopathology
measure with PRS#
Association of log-transformed
psychopathology measure with
PRS#
Association of psychopathology
subscales with PRS#, corrected for
the other subscales
B (95% CI) p n B (95% CI) p n B (95% CI) p n
Measure
CAPE total 0.04 (−0.07 to 0.14) 0.465 911 0.01 (−0.17 to 0.19) 0.917 911 NAa
CAPE positive 0.03 (−0.04 to 0.10) 0.451 910 0.20 (−0.27 to 0.66) 0.400 910 −0.00 (−0.06 to 0.05) 0.872 889
CAPE negative −0.01 (−0.15 to 0.12) 0.848 909 −0.07 (−0.24 to 0.10) 0.431 909 −0.10 (−0.19 to 0.01) 0.030 889
CAPE depressive 0.11 (−0.04 to 0.26) 0.157 911 0.07 (−0.11 to 0.24) 0.441 911 0.08 (−0.01 to 0.18) 0.093 889
SIS-R total 0.16 (0.07–0.25) 0.000 921 0.40 (0.18–0.63) 0.000 921 NAa
SIS-R positive 0.22 (0.10–0.35) 0.000 921 0.60 (0.28–0.93) 0.000 921 0.14 (0.05–0.24) 0.004 889
SIS-R negative 0.11 (0.03–0.19) 0.010 919 0.31 (0.09–0.52) 0.005 919 0.04 (−0.03 to 0.11) 0.244 889
a NA: analyses were conducted with the ﬁve subscales: CAPE positive, CAPE negative, CAPE depressive, SIS-R positive,
SIS-R negative.
#PRS, polygenic risk score; CAPE, Community Assessment of Psychic Experiences (subscales of positive, negative and
depressive symptoms); SIS-R = Structured Interview for Schizotypy – Revised (subscales of positive and negative schizotypy).
Table 7. Results of regression analyses in baseline sample for lifetime manic and depressive episodes (including episodes over 6-year follow-up)
in relatives and healthy comparison subjects. Odds ratio reﬂects association between polygenic risk score on the one hand, and depressive/manic
episode on the other (OR, odds ratio; 95% CI, 95% conﬁdence interval; p, p value; n, number of observations)
Relatives Healthy comparison subjects
OR (95% CI) p n OR (95% CI) p n
Measure
Depressive episode 2.6 (0.9–7.9) 0.089 869 3.4 (0.9–13.0) 0.069 323
Manic episode 6.4 (0.3–132.6) 0.228 869 0.7 (0.01–38.2) 0.867 323
Affective episodea 3.1 (1.04–9.3) 0.043 869 3.4 (0.9–12.7) 0.075 323
a Any depressive or manic episode.
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of affective dysregulation. The effects of polygenic risk
thus may be examined further in network models,
focussing particularly on the strength of the connection
between affective dysregulation, cognition and psych-
otic symptoms. Similarly, gene–environment interac-
tions may converge at the level of the connection
between affective dysregulation, cognition and psych-
otic symptoms.
Cognitive alterations and neurodevelopmental
hypothesis
The premorbid cognitive alterations in schizophrenia
are one of the core ﬁndings supporting the neurodeve-
lopmental hypothesis (Jones et al. 1994). There was evi-
dence for an association between IQ and PRS, however
it may be hypothesized that environmental exposures
such as childhood trauma, that have been shown to
also impact cognitive development (Majer et al. 2010;
Gould et al. 2012; Maguire et al. 2015; Philip et al.
2016) may also play a causal role in the development
of cognitive alterations in psychosis (Lysaker et al.
2001; Aas et al. 2012; Sahu et al. 2016; Van Os et al.
2017). In addition, genetic variation and epistasis not
included in the PRS may contribute to cognitive altera-
tions as well. It has been reported that less than a ﬁfth
of the effect of family history on the occurrence of
psychotic disorder is mediated by PRS (Agerbo et al.
2015), leaving room for the impact of other genetic fac-
tors, assuming not all of the remainder of the effect of
family history is ‘environmental’.
Given evidence that most of the overall effect of a
schizophrenia diagnosis on cognitive performance is
mediated through a single common factor, indicating
that a generalized cognitive deﬁcit is a core underlying
feature (Dickinson et al. 2004), a general measure like
IQ arguably is the most useful to examine in the con-
text of associations with PRS. There have been conﬂict-
ing reports on associations between measures of
cognition and schizophrenia polygenic scores in
patient and control samples using a variety of different
cognitive measures (Hatzimanolis et al. 2015; Hubbard
et al. 2016; Mark & Toulopoulou, 2016), however no
previous report has examined the association in a
large sample of non-ill individuals at higher than aver-
age genetic risk with repeated measures of IQ over
time. Given evidence for an association between PRS
and IQ in healthy control group, it may be hypothe-
sized that PRS for schizophrenia is expressed, at least
in part, as a cognitive measure that correlates with IQ.
Methodological issues
The results should be interpreted in the light of several
methodological considerations. First, although the
sample size was substantial, it was still relatively
small for a molecular genetic study. Nevertheless,
effect sizes were detectable. A previous general popu-
lation study with a larger sample suggested a weak
association with CAPE negative scores however in
that study (Jones et al. 2016), CAPE positive and
CAPE depression scores were not included. Given
that CAPE negative scores are strongly associated
with CAPE depression scores (0.7 in the current
study), the reported association with CAPE negative
scores may be considered compatible with the current
ﬁndings (van Os, 2016), given that CAPE depression in
the healthy comparison group directionally showed
the same type of association as in the relatives, albeit
weaker. In any case, the results of this study show
that self-reports of psychosis-proneness in the general
population may not be sensitive in detecting genetic
associations. Second, it could be argued that lack of
association between IQ and PRS in the relatives cannot
be interpreted fully without examination of the associ-
ation between IQ and PRS in their patient relatives; if
the association is present in the patient group but not
in their relatives, this may indicate that PRS can
contribute to IQ in interaction with other genetic or
non-genetic factors that patients may have been differ-
entially exposed to. However, analysis of the associ-
ation between repeated measure of IQ and PRS in
the patient group (1304 observations in 596 patients)
similarly yielded no evidence of association (B = 1.7,
95% CI −4.5 to 7.9; p = 0.597). Third, it could be argued
that the association between PRS and measures of
affective dysregulation in the relatives is confounded
by PRS-associated poor illness outcome in the patients,
negatively impacting mental health of the relatives.
However, the absence of an association between PRS
and cognitive alterations, which are associated with
poor outcome, makes it unlikely that PRS is associated
with poor outcome. Although PRS was associated with
positive symptoms of psychosis, positive symptoms
are not associated with poor outcome. In order to
verify this issue analytically, we re-examined the asso-
ciation between PRS and CAPE depression, addition-
ally adjusting the analysis for the following outcome
measures in the patient relative: number of unmet
needs, measures with the Camberwell Assessment of
Needs (Slade et al. 1996), GAF-symptoms and
GAF-disability (World Health Organisation, 1992).
This adjustment did not reduce the association (B =
0.22, 95% CI 0.08–0.36, p = 0.003). Finally, although
two different genotyping platforms were used, one
for controls and another for relatives, the use of imput-
ation across platforms can be considered an effective
way to control for this. In addition, analyses in the rela-
tives were entirely within-platform, and analyses in the
healthy comparison subjects was also largely within
platform.
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